HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ ...
The contribution of MALDI mass spectrometry in the field of bacteriology has been well established. For several years now, Biomaneo has demonstrated through NeoSickle® solution the capacity of MALDI ...
Yes, blood tests for Alzheimer’s disease are ready for prime time. So pronounced Suzanne Schindler, Washington University, St. Louis, in a keynote presentation at CTAD 2024 last month in Madrid. In ...
MINNEAPOLIS, March 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro ...
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its NeuMoDx HSV 1/2 Quant Assay for the quantification and ...
MINNEAPOLIS , Feb. 16, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced that the Ella benchtop ...
Hepatitis C assay provides decentralised molecular testing to support the identification of patients that could benefit from direct acting antiviral therapy genedrive plc (LSE:GDR), the molecular ...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE-IVD certification for the BD FACSDuet™ automated flow cytometry system. The new ...
Significant Step inCommercialisation of HCVAssay for Decentralised Use in Resource Limited Settings genedrive plc, the near patient molecular diagnostics company, today announces submission of its ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. CE-IVD certification puts Ella in focus for Bio-Techne investors Bio-Techne (TECH) ...
NEW HAVEN, Conn., May 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that it has received CE-IVD approval for sale of its HemeScreen® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results